USPTO Patent US12583917B2: IL17A Antibodies for Veterinary Use

ChangeBridge: Patent Grants - Peptides (C07K)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12583917B2 to Elanco US Inc. for IL17A antibodies and antagonists intended for treating conditions in animals, including companion animals. The patent details specific antibody embodiments and IgG Fc variant polypeptides designed to reduce immune responses.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12583917B2, assigned to Elanco US Inc. This patent covers embodiments of anti-IL17A antibodies and IL17Ra ECD polypeptides for treating IL17-induced conditions in animals, such as canines, felines, and equines. It also includes IgG Fc variant polypeptides designed to reduce complement-mediated immune responses and antibody-dependent cell-mediated cytotoxicity.

This patent grant is primarily an intellectual property development and does not impose new regulatory obligations on regulated entities. However, it signifies a new proprietary development in veterinary therapeutics that may influence future market competition and product development strategies for companies operating in the animal health sector.

Source document (simplified)

← USPTO Patent Grants

IL17A antibodies and antagonists for veterinary use

Grant US12583917B2 Kind: B2 Mar 24, 2026

Assignee

Elanco US Inc.

Inventors

Shyr Jiann Li, Lam Nguyen, Lan Yang, Hangjun Zhan

Abstract

Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.

CPC Classifications

C07K 16/244 C07K 2317/24 C07K 2317/31 C07K 2317/33 C07K 2317/56 C07K 2317/565 C07K 2317/76 C07K 2317/524 C07K 2317/34 C07K 2317/71 C07K 2317/734 C07K 2317/92 C07K 2319/30 C07K 14/7155 A61K 39/3955 A61K 2039/505 C12N 15/63 A61P 37/00